Engineered ovalbumin-expressing regulatory T cells protect against anaphylaxis in ovalbumin-sensitized mice

被引:22
作者
Abdeladhim, Maha [1 ]
Zhang, Ai-Hong [1 ]
Kropp, Laura E. [2 ]
Lindrose, Alyssa R. [2 ]
Venkatesha, Shivaprasad H. [1 ]
Mitre, Edward [2 ]
Scott, David W. [1 ]
机构
[1] Uniformed Serv Univ Hlth Sci, Dept Med, Bethesda, MD 20814 USA
[2] Uniformed Serv Univ Hlth Sci, Dept Microbiol & Immunol, Bethesda, MD 20814 USA
关键词
THERAPY; RESPONSES;
D O I
10.1016/j.clim.2019.07.009
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Allergy is a major public health concern, the main treatment for which is symptomatic relief with anti-inflammatory drugs. A key clinical challenge is to induce specific tolerance in order to control allergen-specific memory B and T cells, and specifically block effector cell responses. Our lab recently developed antigen-specific regulatory T-cell (Treg) therapies as a treatment for adverse responses. Recently, we created a chimeric antigen receptor (CAR) approach in which we engineered a target protein antigen, ovalbumin (OVA), linked with the transmembrane and signal transduction domains, CD28-CD3 zeta to directly target B cells and sensitized mast cells in an allergy model. We named this receptor "BAR" for B-cell Antibody Receptor. Murine or human Tregs, transduced with a BAR containing OVA or control Tregs expressing an unrelated antigen, were successfully expanded in vitro and tested in the murine OVA-alum allergy model with measurable titers of anti-OVA IgE. Because BAR Tregs express the target antigen and could interact with specific IgE on sensitized mast cells, we first demonstrated that intravenously injected OVA-BAR Tregs did not directly lead to a drop in temperature or release of mediators in plasma indicative of anaphylaxis. Forty-eight hours later, mice were challenged intraperitoneally with 200 mu g OVA to induce an anaphylactic reaction, and temperature immediately measured for 30 min. We found that OVA-BAR Tregs protected mice from hypothermia, whereas mice given control BARs (expressing an unrelated antigen) or PBS showed substantial temperature drops indicative of anaphylaxis when systemically challenged with OVA. Importantly, this effect was also demonstrated in a passive anaphylaxis model in which mice that received anti-OVA IgE antibody were protected from hypothermia when treated with OVA-BAR Tregs prior to systemic OVA challenge. These results provide proof of principle that engineered allergen-specific T-regulatory cells can provide clinical protection against severe allergic reactions in individuals already IgE-sensitized to an allergen.
引用
收藏
页码:49 / 54
页数:6
相关论文
共 18 条
[1]   Human Tregs Made Antigen Specific by Gene Modification: The Power to Treat Autoimmunity and Antidrug Antibodies with Precision [J].
Adair, Patrick R. ;
Kim, Yong Chan ;
Zhang, Ai-Hong ;
Yoon, Jeongheon ;
Scott, David W. .
FRONTIERS IN IMMUNOLOGY, 2017, 8
[2]   Immune regulatory cell infusion for graft-versus-host disease prevention and therapy [J].
Blazar, Bruce R. ;
MacDonald, Kelli P. A. ;
Hill, Geoffrey R. .
BLOOD, 2018, 131 (24) :2651-2660
[3]   Adoptive Transfer of Umbilical Cord Blood-Derived Regulatory T Cells and Early Viral Reactivation [J].
Brunstein, Claudio G. ;
Blazar, Bruce R. ;
Miller, Jeffrey S. ;
Cao, Qing ;
Hippen, Keli L. ;
McKenna, David H. ;
Curtsinger, Julie ;
McGlave, Philip B. ;
Wagner, John E. .
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2013, 19 (08) :1271-1273
[4]   Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease [J].
Ellebrecht, Christoph T. ;
Bhoj, Vijay G. ;
Nace, Arben ;
Choi, Eun Jung ;
Mao, Xuming ;
Cho, Michael Jeffrey ;
Di Zenzo, Giovanni ;
Lanzavecchia, Antonio ;
Seykora, John T. ;
Cotsarelis, George ;
Milone, Michael C. ;
Payne, Aimee S. .
SCIENCE, 2016, 353 (6295) :179-184
[5]   Regulatory T-cell therapy for autoimmune and autoinflammatory diseases: The next frontier [J].
Esensten, Jonathan H. ;
Muller, Yannick D. ;
Bluestone, Jeffrey A. ;
Tang, Qizhi .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2018, 142 (06) :1710-1718
[6]   Regulatory T cell therapy for type 1 diabetes: May the force be with you [J].
Gitelman, Stephen E. ;
Bluestone, Jeffrey A. .
JOURNAL OF AUTOIMMUNITY, 2016, 71 :78-87
[7]   CD4+CD25+ Regulatory T Cells Suppress Mast Cell Degranulation and Allergic Responses through OX40-OX40L Interaction [J].
Gri, Giorgia ;
Piconese, Silvia ;
Frossi, Barbara ;
Manfroi, Vanessa ;
Merluzzi, Sonia ;
Tripodo, Claudio ;
Viola, Antonella ;
Odom, Sandra ;
Rivera, Juan ;
Colombo, Mario P. ;
Pucillo, Carlo E. .
IMMUNITY, 2008, 29 (05) :771-781
[8]   Rush desensitization with a single antigen induces subclinical activation of mast cells and protects against bystander challenge in dually sensitized mice [J].
Killoran, Kristin E. ;
Kropp, Laura E. ;
Lindrose, Alyssa R. ;
Curtis, Holly E. ;
Cook, David ;
Mitre, Edward .
CLINICAL AND EXPERIMENTAL ALLERGY, 2019, 49 (04) :484-494
[9]   Engineered antigen-specific human regulatory T cells: immunosuppression of FVIII-specific T- and B-cell responses [J].
Kim, Yong Chan ;
Zhang, Ai-Hong ;
Su, Yan ;
Rieder, Sadiye Amcaoglu ;
Rossi, Robert J. ;
Ettinger, Ruth A. ;
Pratt, Kathleen P. ;
Shevach, Ethan M. ;
Scott, David W. .
BLOOD, 2015, 125 (07) :1107-1115
[10]   Distinct regulation of IgE, IgG4 and IgA by T regulatory cells and toll-like receptors [J].
Meiler, F. ;
Klunker, S. ;
Zimmermann, M. ;
Akdis, C. A. ;
Akdis, M. .
ALLERGY, 2008, 63 (11) :1455-1463